Continuous-flow process for methylphenidate hydrochloride preparation

Continuous-flow process for methylphenidate hydrochloride preparation

The patented technology consists in an alternate more cost effective process for the preparation of the active pharmaceutical ingredient threo-methylphenidate hydrochloride, a central nervous system stimulant.

Specific process conditions were developed to meet the specific requirements of continuous-flow reactors.

This work fits in the actual context of developing efficient continuous-flow processes for the continuous manufacturing of active pharmaceutical ingredients.


Probiotic bacteria: new species

Probiotic bacteria: new species

Two new patented Bifidobacterium species, B. crudilactis sp. nov. (100 strains) and B. mongoliense sp. nov. (20 strains) have been isolated from raw milk and raw milk cheese.

Those species can easily be integrated into various manufacturing processes and stabilized in food and fermented products.

Potential for immunomodulatory effects and good resistance to biological barriers.


A new Laparoscopic Reverse Stapler for Bariatric Surgery

A new Laparoscopic Reverse Stapler for Bariatric Surgery

Obesity has become the first non-infectious disease in history and the WHO up its prevention and care as a priority in the field of nutritional pathology. Bariatric surgery stays the principal option for the treatment of severe obesity and needs specific medical instruments like endoscopic staplers.

The Department of Abdominal Surgery of Liège University Hospital (CHU de Liège), together with Vilecon (Danish company), has developed a new Laparoscopic Reverse Stapler that is less invasive, simplifies the surgical procedure and likely decreases the potential complications associated to this technique.


Innovative chitosan-based biomimetic scaffold for wound repair and tissue engineering

Innovative chitosan-based biomimetic scaffold for wound repair and tissue engineering

Our researchers at the ULg have developed an innovative chitosan-based scaffold for wound repair and tissue engineering. This new scaffold-type has unique structural properties that stimulate the healing process and improve of the overall quality of the repaired tissue through a more adequate revascularization, re-epithelialization and remodeling of the granulation tissue. Easy-to-handle, and large potential for re-modelling.


Scaffold for the cultivation of cartilage-forming cells

Scaffold for the cultivation of cartilage-forming cells

The present invention relies upon a new scaffold based on chitosan/alginate hydrogel beads, for the cultivation of cartilage-forming cells.

The combination of chitosan and alginate might improve traumatic or degenerative cartilage lesion treatment. Compared to other types of cellularised beads, the present beads can be prepared in a more reproducible way: stabilization of the chondrocytes’ phenotype, while ensuring an optimal space distribution of cells in the host tissue or organ.

 


New Synthetic Antidote of Heparin

New Synthetic Antidote of Heparin

This synthetic hemocompatible polymer is an elegant high-quality alternative to protamine-sulphate (PS) for the rapid and efficient neutralization of heparin (non fractionated and fractionated) in complex biological media such as human plasma.

The synthetic nature of this heparin antidote allows to overcome most of the challenges faced by PS, ie like residues, purity, supply, and consistency while maintaining a similar efficacy and onset of action.


A new target to optimize anti-EGFR therapies

A new target to optimize anti-EGFR therapies

Our researchers at University of Liège have established an unexpected functional link between MT4-MMP (MMP-17) and EGFR pathway that allows optimizing treatment and prediction of the responsiveness to anti-EGFR in cancer therapy.


Prolactin/growth hormone derived peptides to treat thrombotic disorders

Prolactin/growth hormone derived peptides to treat thrombotic disorders

Our scientists have previously reported that members of the prolactin/growth hormone family (PRL/GH) stimulate angiogenesis whereas, in contrast, their N-terminal fragments display antiangiogenic properties. These peptides contain the N-terminal region of PRL/ GH and exhibit molecular masses ranging from 14 to 16 kDa. They are thus named 16K PRL and 14K GH. Recent data identify Plasminogen Activator Inhibitor type 1 (PAI-1) as their binding partner.